Association Study of the Complement Component C4 Gene in Tardive Dyskinesia.
antipsychotic
complement component C4
pharmacogenetics
schizophrenia
tardive dyskinesia (TD)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
07
2019
accepted:
18
10
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
19
12
2019
Statut:
epublish
Résumé
Tardive dyskinesia (TD) is a movement disorder that may develop in schizophrenia patients being treated long-term with antipsychotic medication. TD interferes with voluntary movements and leads to stigma, and can be associated with treatment non-adherence. The etiology of TD is unclear, but it appears to have a genetic component. There is emerging evidence of immune dysregulation in TD. In the current study, we set out to investigate the complex schizophrenia-associated complement component 4 (
Identifiants
pubmed: 31849639
doi: 10.3389/fphar.2019.01339
pmc: PMC6901959
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1339Informations de copyright
Copyright © 2019 Zai, Tiwari, Zai, Freeman, Pouget, Greco, Tampakeras, Shaikh, Herbert, Emmerson, Cheema, Braganza, Müller, Voineskos, Remington and Kennedy.
Références
Schizophr Res. 2015 Mar;162(1-3):261-8
pubmed: 25600548
Biol Psychiatry. 2010 Feb 1;67(3):279-82
pubmed: 19875103
Nature. 2009 Aug 6;460(7256):744-7
pubmed: 19571808
Int J Neuropsychopharmacol. 2007 Oct;10(5):639-51
pubmed: 16959057
Int Immunol. 2008 Jan;20(1):31-7
pubmed: 18032375
Am J Psychiatry. 1981 Dec;138(12):1618-9
pubmed: 6118067
J Immunol. 2003 Sep 1;171(5):2734-45
pubmed: 12928427
J Neurol Sci. 2018 Jun 15;389:28-34
pubmed: 29502799
Front Pharmacol. 2018 Sep 18;9:974
pubmed: 30283332
Curr Opin Psychiatry. 2018 May;31(3):200-212
pubmed: 29528898
J Clin Psychiatry. 1981 Apr;42(4):165-6
pubmed: 6110655
Immunogenetics. 2004 Aug;56(5):321-32
pubmed: 15309346
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Lupus. 2018 Apr;27(4):600-609
pubmed: 29050534
J Neuroimmune Pharmacol. 2015 Sep;10(3):425-34
pubmed: 25850894
J Cereb Blood Flow Metab. 2007 Dec;27(12):1954-64
pubmed: 17457366
Acta Psychiatr Scand. 1994 Nov;90(5):311-5
pubmed: 7872033
Mol Psychiatry. 2020 Jan;25(1):114-130
pubmed: 31439935
J Immunol. 2007 Sep 1;179(5):3012-25
pubmed: 17709516
Exp Neurol. 1999 Oct;159(2):362-76
pubmed: 10506508
Int Rev Neurobiol. 2011;98:231-64
pubmed: 21907090
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:259-64
pubmed: 24995685
Int Immunopharmacol. 2001 Mar;1(3):365-92
pubmed: 11367523
Nature. 2016 Feb 11;530(7589):177-83
pubmed: 26814963
Nucleic Acids Res. 1991 Oct 11;19(19):5444
pubmed: 1681511
Transl Psychiatry. 2017 Mar 28;7(3):e1075
pubmed: 28350400
Psychiatry Res. 2012 Jul 30;198(2):329-31
pubmed: 22417931
Arch Gen Psychiatry. 1982 Apr;39(4):486-7
pubmed: 6121550
Nature. 2009 Aug 6;460(7256):753-7
pubmed: 19571809
Acta Psychiatr Scand. 2001 Nov;104(5):375-9
pubmed: 11722319
PLoS One. 2013 Aug 07;8(8):e70963
pubmed: 23951054
J Neuroinflammation. 2016 Apr 07;13(1):72
pubmed: 27056040
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):106-10
pubmed: 22227290
Sci Rep. 2017 Feb 16;7:42628
pubmed: 28205620
J Psychiatr Res. 2013 Nov;47(11):1760-5
pubmed: 24018103
J Psychiatr Res. 2018 Jan;96:265-272
pubmed: 29301639
Psychopharmacology (Berl). 2016 May;233(9):1559-73
pubmed: 26037944
Schizophr Res. 2009 Apr;109(1-3):167-81
pubmed: 19261444